The 40%# I believe is a mix of the low 1st qtr #. Look back to previous quarters and it seems 20-25% growth rate may be more realistic. ..... But I'd take 40%. :)
Great reply! Only thing I'd add\differ on is the $900M comment. Eriv sales continue to grow, 3 drugs in pipeline show good results, and the Eriv in the IPF trial shows results I believe the $900M will easily get hit.
Sentiment: Strong Buy
Still on schedule. Another target now being painted by chart pattern being formed, 5 area.
Sentiment: Strong Sell
There are 4 presentations next week.
ROTH Healthcare Corporate Access Day in London: June 23-24, 2014
2014 BIO International Convention in San Diego: June 23-26, 2014
JMP Securities Healthcare Conference in New York: June 24-25, 2014
Janney Capital Markets Boston Healthcare 1x1 Corporate Access Day: June 26, 2014
I'll only say\start by saying we are not waiting for P2 results on non-operable and leave it at that. Sorry for the forwardness-just not a fan of misinformation.
Usually don't consider time but having been with this for 3 years now and charting it extensively; it can ramp quickly at times....kinda like the 35-40% in the past 2 months. :)
Thx Rym. Just quietly riding along here while involved in some interesting projects elsewhere. Been seeing\hearing some good artists\music past few years...striking them off the bucket list. B